Close Menu

NEW YORK – miRagen Therapeutics said on Thursday that it received guidance from the US Food and Drug Administration on registration-enabling development plans for cobomarsen as a treatment for T-cell leukemia/lymphomas with microRNA-155 overexpression.

Boulder, Colorado-based miRagen said in a statement that the "now defined regulatory pathway for potential approval of cobomarsen for both CTCL and ATLL is an important incremental step" in the broader program strategy to study cobomarsen's efficacy in a variety of miR-155 elevated blood cancers.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.